RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROGRAM - PROJECT #6658
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N92021C00007-0-9999-1
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20212022Known Financial Commitments (USD)
$10,295,000Funder
National Institutes of Health (NIH)Principal Investigator
DAVID YOOResearch Location
South KoreaLead Research Institution
GENBODY INC.Research Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
A method was developed to detect not only SARS-CoV-2, but also influenza A and Influenza B anigen at the same time in a single lateral flow rapid testing (LFRT) system. The kit is a single device that can detect SARS-CoV-2 antigen and influenza antigen simultaneously. Since Influenza with respiratory illness with symptoms of high fever is similar to COVID-19, there are many difficulties to distinguish it from clinical diagnosis. Influenza can be treated with antiviral drugs such as Tamiflu, and there are also defense measures such as vaccines, so the treatment method is different. We have developed and evaluated an analytical/clinical performance for rapid diagnosis kit of SARS-CoV-2 antigen, obtained approval from the Korean Food and Drug Administration, and diagnostic Kits for influenza A/B antigen have also been licensed and commercialized. This diagnostic kit is basically diagnosed through the naked eye, and a portable equipment (Confiscope G20 has CE but no FCC) can be used for accurate determination which can be applied to control systems using a network.